Trial Profile
A Phase 1 Randomized, Double Blind, Placebo Controlled, Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NGM313 in Healthy Overweight and Obese Adult Participants
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Sep 2017
Price :
$35
*
At a glance
- Drugs MK 3655 (Primary)
- Indications Obesity
- Focus First in man; Therapeutic Use
- Sponsors NGM Biopharmaceuticals
- 13 Sep 2017 Status changed from active, no longer recruiting to completed.
- 07 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Jun 2016 Data from the trial are expected in 2017, according to an NGM Biopharmaceuticals media release.